Evoke Pharma, Inc. (EVOK): Marketing Mix Analysis [Dec-2025 Updated]

You're digging into Evoke Pharma, Inc. right as a major pivot point hits-the proposed QOL Medical acquisition-and you need to know if the underlying business is solid. Honestly, the commercial story is compelling: their sole product, GIMOTI®, is showing real traction, pushing full-year 2025 sales guidance toward $16 million, a 60% leap from last year, supported by a 70% patient refill rate. Before we assess the deal's impact, let's quickly map out the four pillars-Product, Place, Promotion, and Price-that built this momentum, so you see exactly what's on the table.

Evoke Pharma, Inc. (EVOK) - Marketing Mix: Product

Evoke Pharma, Inc. (EVOK)'s product strategy centers entirely on its sole commercial offering, GIMOTI® (metoclopramide) nasal spray.

GIMOTI® is FDA-approved for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. This product is significant because metoclopramide is the only drug currently approved in the United States to treat gastroparesis, and GIMOTI® provides a non-oral alternative to the previously available oral and injectable formulations. The indication specifically targets patients with moderate to severe symptoms of the condition.

The company has taken steps to secure a long commercial life for this asset. A new U.S. patent, specifically U.S. Patent No. 12,377,064, has been listed in the FDA's Orange Book. This patent covers the use of intranasal metoclopramide for patients with moderate to severe gastroparesis symptoms and extends expected exclusivity until November 17, 2038, due to patent term adjustments (PTA). Evoke Pharma, Inc. is also pursuing additional related claims via a continuation application.

Evoke Pharma, Inc.'s strategic focus is clearly directed toward addressing evolving patient needs, particularly within the growing population using GLP-1 agonists, who often experience gastrointestinal side effects. Real-world data presented at Digestive Disease Week (DDW) 2025 compared the incidence of tardive dyskinesia among continuous versus intermittent metoclopramide use. Furthermore, data presented at ACG 2024 highlighted GIMOTI's potential to treat diabetic gastroparesis even in patients undergoing GLP-1 therapy.

Commercial performance metrics for GIMOTI® in 2025 demonstrate increasing adoption and utilization:

• Net product sales for the first quarter of 2025 reached approximately $3.1 million, a 77% year-over-year increase.
• Net product sales for the second quarter of 2025 reached approximately $3.8 million, a 47% year-over-year increase.
• The company confirmed its full-year 2025 net product sales guidance of approximately $16 million.
• The gross profit margin was reported at 96.6% as of August 2025.

The following table summarizes key commercial execution statistics for GIMOTI® as reported through the first half of 2025:

The product's value proposition is rooted in its delivery mechanism, which bypasses the absorption issues common with oral medications in gastroparesis patients. This is reflected in the strong refill rates, which held steady at approximately 70% in the second quarter of 2025.

Evoke Pharma, Inc. (EVOK) - Marketing Mix: Place

You're looking at how Evoke Pharma, Inc. gets GIMOTI into the hands of the right patients. Distribution is all about the channels and partnerships that make this nasal spray available where U.S. gastroenterologists (GI) practice.

Distribution is managed through a commercialization partnership with EVERSANA. Evoke Pharma, Inc. retains ownership of the GIMOTI New Drug Application (NDA) and manufacturing responsibilities, but EVERSANA handles market access, marketing, distribution, and patient support services. Evoke records the sales for GIMOTI and retains more than 80% of the net product profits after EVERSANA's costs are reimbursed. This commercialization agreement is extended through the end of 2026. The second quarter of 2025 saw selling, general, and administrative expenses increase due to higher profit-sharing activity with EVERSANA, which resulted from an increase in net product sales.

The company has actively expanded pharmacy access via new partnerships with Omnicell and Brentwood Pharmacy. These relationships, announced in August 2025, are strategic moves to align with specialty pharmacies that GI physicians use. The integration with Omnicell is specifically intended to ensure better alignment with specialty pharmacies used by large GI group practices.

This expansion directly leads to enhanced distribution network access through groups like Gastro Health and OneGI. The Omnicell relationship is expected to almost double the number of specialty pharmacies available for GIMOTI access.

Here's a breakdown of the networks involved in this expanded access:

• Gastro Health has a presence in 7 states and 150 locations.
• OneGI, which is accessed via the Brentwood Pharmacy agreement, manages approximately 200 gastroenterologists and specialized physician assistants.
• OneGI has offices located in Tennessee, Kentucky, Ohio, Mississippi, and surrounding states.

The primary market is the U.S. gastroenterology (GI) clinic channel, as GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

The entire commercial structure is built around a single asset, meaning the company is entirely dependent on the success of GIMOTI distribution. The financial performance directly reflects this distribution success.

The refill rate, a key indicator of patient usage and distribution effectiveness, held steady at approximately 70% as of the second quarter of 2025. This consistent usage is what supports the full-year sales guidance. Finance: draft Q4 2025 cash flow projection by next Tuesday.

Evoke Pharma, Inc. (EVOK) - Marketing Mix: Promotion

The promotional strategy for Evoke Pharma, Inc. (EVOK) centers on driving adoption of GIMOTI® within U.S. gastroenterology clinics by demonstrating clinical value and ensuring patient access.

Clinical adoption metrics from the second quarter of 2025 show tangible progress in reaching the target audience. New prescribers increased by 20% year-over-year, signaling broadening engagement among healthcare providers for the treatment of diabetic gastroparesis. Furthermore, patient adherence, a key indicator of perceived therapeutic benefit, is supported by a high prescription refill rate holding steady at approximately 70% as of Q2 2025.

Key promotional activities include the presentation of scientific data at major medical gatherings. Evoke Pharma presented real-world safety data at Digestive Disease Week (DDW) 2025, which took place from May 3-6, 2025, in San Diego, CA. The specific poster presentation, titled Comparison of the Incidence of Tardive Dyskinesia in Patients Receiving Continuous vs Intermittent Oral Metoclopramide, was presented on Monday, May 5, 2025, from 12:30 - 1:30 p.m. PT. This analysis leveraged real-world data encompassing over 100 million U.S. patients to clarify risk profiles associated with metoclopramide dosing patterns.

The commercialization engine relies heavily on external infrastructure and specialized internal support functions to manage the payer landscape, which directly impacts patient access and prescription fulfillment. Evoke Pharma's selling, general, and administrative (SG&A) expenses for the second quarter of 2025 were approximately $5.1 million, up from $3.7 million for the same period in 2024. This increase included higher profit-sharing activity with EVERSANA, which supports the sales and marketing infrastructure, directly tied to the 47% year-over-year increase in net product sales to $3.8 million in Q2 2025.

The focus on streamlining patient access involves deploying specialized personnel to navigate complex payer policies, a function often executed by field reimbursement managers. This effort supports the conversion of prescriptions to fills, which is critical for revenue realization.

The promotional activities and associated commercial infrastructure can be summarized by the following operational focus areas:

• Focus on adoption within U.S. gastroenterology clinics.
• Real-world safety data presented at DDW 2025.
• Commercial support provided by the EVERSANA infrastructure.
• Field reimbursement managers deployed to navigate payer policies.
• Patient adherence indicated by a 70% refill rate.

Evoke Pharma, Inc. (EVOK) - Marketing Mix: Price

The pricing element for Evoke Pharma, Inc. centers on the net realization from product sales, which is heavily influenced by payer dynamics and commercial partner costs. This strategy aims to capture value while ensuring patient access to GIMOTI® (metoclopramide) nasal spray.

Evoke Pharma, Inc. has confirmed its full-year 2025 net product sales guidance is approximately $16 million, which represents a projected 60% increase over 2024 net product sales. This revenue projection is a key indicator of the expected average realized price across the year, factoring in all payer negotiations and patient out-of-pocket costs.

Commercial momentum is reflected in the quarterly revenue figures. Net product sales for the third quarter of 2025 were approximately $4.3 million. Year-to-date sales through Q3 2025 reached $11.1 million, marking a 60% increase compared to the first three quarters of 2024. The Q3 2025 net product sales of $4.3 million were up 61% year-over-year from Q3 2024 sales of approximately $2.7 million.

The underlying pricing strategy incorporates specific assumptions regarding favorable payer reimbursements and conversion rates from prescription to filled prescription. Furthermore, increased insurance coverage is noted as a factor reducing patient reliance on savings programs, which directly impacts the net price received by Evoke Pharma, Inc. for each unit sold.

Cost of sales execution directly impacts the effective price realization. Selling, general, and administrative (SG&A) expenses are a significant component of the cost structure tied to commercialization. For the second quarter of 2025, SG&A expenses were approximately $5.1 million, up from approximately $3.7 million in Q2 2024. By the third quarter of 2025, SG&A expenses rose to approximately $5.3 million, compared to $3.8 million in Q3 2024. This increase in SG&A is partly attributed to a $1.3 million rise in marketing and profit-sharing activity with Eversana, which scales with higher net product sales.

A critical financial price point related to the company's valuation, which impacts shareholder price realization, was the definitive agreement announced on November 4, 2025, for QOL Medical to acquire Evoke Pharma, Inc. at a price of $11.00 per share in cash.

Here is a comparison of key financial metrics impacting the price realization and cost structure:

Key operational metrics that underpin the pricing power and patient access include:

• Refill rates held steady at approximately 70% in Q2 2025.
• Refill rate was 73% year-over-year increase in Q1 2025.
• New prescribers grew 20% year-over-year in Q2 2025.
• Total prescriber base grew 44% year-over-year in Q1 2025.